Literature DB >> 15790992

Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

M Decramer1, R Gosselink, P Bartsch, C-G Löfdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, T Troosters.   

Abstract

During the last decade several long term studies of interventions in patients with COPD have been published. This review analyses the potential of these interventions to alter the progression of the condition. The only treatment that has unequivocally been shown to reduce the rate of decline in FEV(1) is smoking cessation. Active psychological intervention in combination with pharmacotherapy is required. Other treatments may have an effect on the rate of decline in FEV(1) but this appears to be very small, at most. Several treatments affect the exacerbation rate and therefore might affect the progression of the disease. Further studies are warranted to examine this effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790992      PMCID: PMC1747377          DOI: 10.1136/thx.2004.028720

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  75 in total

1.  Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994.

Authors:  D M Mannino; R C Gagnon; T L Petty; E Lydick
Journal:  Arch Intern Med       Date:  2000-06-12

2.  Quality of life changes in COPD patients treated with salmeterol.

Authors:  P W Jones; T K Bosh
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

3.  Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease.

Authors:  E Sala; J Roca; R M Marrades; J Alonso; J M Gonzalez De Suso; A Moreno; J A Barberá; J Nadal; L de Jover; R Rodriguez-Roisin; P D Wagner
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

Review 4.  Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease.

Authors:  W Macnee; I Rahman
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

5.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

Authors:  G Boyd; A H Morice; J C Pounsford; M Siebert; N Peslis; C Crawford
Journal:  Eur Respir J       Date:  1997-04       Impact factor: 16.671

6.  Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

Authors:  R E Kanner; N R Anthonisen; J E Connett
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

7.  Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.

Authors:  P M Calverley; W Boonsawat; Z Cseke; N Zhong; S Peterson; H Olsson
Journal:  Eur Respir J       Date:  2003-12       Impact factor: 16.671

8.  A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group.

Authors:  H A Kerstjens; P L Brand; M D Hughes; N J Robinson; D S Postma; H J Sluiter; E R Bleecker; P N Dekhuijzen; P M de Jong; H J Mengelers
Journal:  N Engl J Med       Date:  1992-11-12       Impact factor: 91.245

Review 9.  Contemporary management of chronic obstructive pulmonary disease: scientific review.

Authors:  Don D Sin; Finlay A McAlister; S F Paul Man; Nick R Anthonisen
Journal:  JAMA       Date:  2003-11-05       Impact factor: 56.272

10.  Pharmacologic control of plasma exudation into tracheobronchial airways.

Authors:  I Erjefält; C G Persson
Journal:  Am Rev Respir Dis       Date:  1991-05
View more
  6 in total

1.  Association of Hck genetic polymorphisms with gene expression and COPD.

Authors:  Xiaozhu Zhang; Salahaddin Mahmudi-Azer; John E Connett; Nicholas R Anthonisen; Jian-Qing He; Peter D Paré; Andrew J Sandford
Journal:  Hum Genet       Date:  2006-09-26       Impact factor: 4.132

2.  The validity of diagnostic support of an asthma/COPD service in primary care.

Authors:  Annelies Lucas; Frank Smeenk; Ivo Smeele; Tim Brouwer; Onno van Schayck
Journal:  Br J Gen Pract       Date:  2007-11       Impact factor: 5.386

3.  Validation of smoking cessation self-reported by patients with chronic obstructive pulmonary disease.

Authors:  Sander R Hilberink; Johanna E Jacobs; Sanne van Opstal; Trudy van der Weijden; Janine Keegstra; Pascal Lj Kempers; Jean Wm Muris; Richard Ptm Grol; Hein de Vries
Journal:  Int J Gen Med       Date:  2011-01-23

Review 4.  Changing the burden of COPD mortality.

Authors:  David M Mannino; Victor A Kiriz
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 5.  Airway disease: similarities and differences between asthma, COPD and bronchiectasis.

Authors:  Rodrigo Athanazio
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

6.  Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM.

Authors:  A Brekkan; S Jönsson; M O Karlsson; E L Plan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-26       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.